JP2023500889A5 - - Google Patents

Info

Publication number
JP2023500889A5
JP2023500889A5 JP2022526005A JP2022526005A JP2023500889A5 JP 2023500889 A5 JP2023500889 A5 JP 2023500889A5 JP 2022526005 A JP2022526005 A JP 2022526005A JP 2022526005 A JP2022526005 A JP 2022526005A JP 2023500889 A5 JP2023500889 A5 JP 2023500889A5
Authority
JP
Japan
Prior art keywords
seq
composition according
approximately
ntki
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022526005A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023500889A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2020/000969 external-priority patent/WO2021090069A1/en
Publication of JP2023500889A publication Critical patent/JP2023500889A/ja
Publication of JP2023500889A5 publication Critical patent/JP2023500889A5/ja
Pending legal-status Critical Current

Links

JP2022526005A 2019-11-07 2020-11-06 非チロシン標的化キナーゼ阻害剤との併用における成長因子抗体の使用のための方法及び組成物 Pending JP2023500889A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962932131P 2019-11-07 2019-11-07
US62/932,131 2019-11-07
US202063094018P 2020-10-20 2020-10-20
US63/094,018 2020-10-20
PCT/IB2020/000969 WO2021090069A1 (en) 2019-11-07 2020-11-06 Methods and compositions for use of growth factor antibodies in combination with non-tyrosine targeting kinase inhibitors

Publications (2)

Publication Number Publication Date
JP2023500889A JP2023500889A (ja) 2023-01-11
JP2023500889A5 true JP2023500889A5 (enExample) 2023-11-15

Family

ID=74106061

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022526005A Pending JP2023500889A (ja) 2019-11-07 2020-11-06 非チロシン標的化キナーゼ阻害剤との併用における成長因子抗体の使用のための方法及び組成物

Country Status (11)

Country Link
US (1) US20220378891A1 (enExample)
EP (1) EP4054619A1 (enExample)
JP (1) JP2023500889A (enExample)
KR (1) KR20220099990A (enExample)
CN (1) CN115379851A (enExample)
AU (1) AU2020378682A1 (enExample)
BR (1) BR112022008704A2 (enExample)
CA (1) CA3157334A1 (enExample)
IL (1) IL292730A (enExample)
MX (1) MX2022005306A (enExample)
WO (1) WO2021090069A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20160685A1 (es) 2013-10-04 2016-07-23 Infinity Pharmaceuticals Inc Compuestos heterociclicos y usos de los mismos
US10160761B2 (en) 2015-09-14 2018-12-25 Infinity Pharmaceuticals, Inc. Solid forms of isoquinolinones, and process of making, composition comprising, and methods of using the same
WO2023159184A1 (en) * 2022-02-18 2023-08-24 Pattern Computer, Inc. Drug combinations and methods of treating ovarian cancer

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
BR112014012460B1 (pt) 2011-11-23 2021-01-12 Bioven 3 Limited proteínas recombinantes
AU2013360335B2 (en) * 2012-12-13 2017-12-07 Immunomedics, Inc. Dosages of immunoconjugates of antibodies and SN-38 for improved efficacy and decreased toxicity
KR102391734B1 (ko) 2013-03-15 2022-04-29 인3바이오 리미티드 자기조립형 합성 단백질
EP3454864A4 (en) * 2016-04-21 2021-01-13 Abbvie Stemcentrx LLC Novel anti-bmpr1b antibodies and methods of use
JP2019536783A (ja) * 2016-11-30 2019-12-19 タイム，インコーポレーテッド チロシン誘導体及びそれらを含む組成物
CN110381997A (zh) * 2016-12-12 2019-10-25 茂体外尔公司 用于治疗和预防癌症和感染性疾病的包含病毒基因治疗和免疫检查点抑制剂的方法和组合物
WO2018175251A1 (en) * 2017-03-20 2018-09-27 Celcuity Llc Methods of measuring signaling pathway activity for selection of therapeutic agents
IL300235A (en) * 2017-07-18 2023-03-01 In3Bio Ltd Synthetic proteins and their therapeutic uses
AU2018329925B2 (en) * 2017-09-08 2025-05-29 F. Hoffmann-La Roche Ag Diagnostic and therapeutic methods for cancer

Similar Documents

Publication Publication Date Title
EP2712320B1 (en) Method for egfr directed combination treatment of cancer
RU2762746C2 (ru) Применение комбинации антитела к pd-1 и ингибитора vegfr в изготовлении лекарственного средства для лечения злокачественных новообразований
CN101998851A (zh) 吡铂和西妥昔单抗治疗结直肠癌的用途
JP2019517549A5 (enExample)
GB2531094A (en) Anti-B7-H1 and Anti-CTLA-4 antibodies for treating non-small cell lung cancer
CA2792327A1 (en) Use of erbb3 inhibitors in the treatment of triple negative and basal-like breast cancers
JP2007297398A (ja) 突然変異上皮成長因子受容体を標的とする試薬および方法
JP6410795B2 (ja) カルボキシアミドトリアゾールオロテートを使用する、先の化学療法薬および標的薬物に対する獲得耐性を持つ癌を治療するための方法および組成物
TW202329946A (zh) 用於治療癌症之方法及包含cdk2抑制劑之給藥方案
US20230070988A1 (en) Combinations of egfr inhibitors and ror1 inhibitors for the treatment of cancer
JP2024521696A5 (enExample)
WO2025103377A1 (zh) 抗b7h3抗体-药物偶联物治疗癌症的方法
AU2019409139A1 (en) Use of IL-1β binding antibodies
CN119604291A (zh) Blu-945联合奥斯替尼治疗非小细胞肺癌
US20230321087A1 (en) Fgfr inhibitor combination therapies
WO2023281413A1 (en) Methods and dosing regimens comprising pf-06873600 for the treatment of cancer
JP2024516970A5 (enExample)
WO2026103823A1 (zh) Ras抑制剂和egfr抑制剂的组合及其用途
WO2026103822A1 (zh) Ras抑制剂和pd-1或pd-l1抑制剂的组合及其用途
WO2026019991A1 (en) Combinations comprising a kras g12c inhibitor, pembrolizumab and a steroid
WO2023111810A1 (en) Combination therapies and uses for treating cancer
EP4359003A1 (en) Erk1/2 and egfr inhibitors combination therapy
CN117858725A (zh) Erk1/2和egfr抑制剂组合疗法
HK40085445A (en) Combinations of egfr inhibitors and ror1 inhibitors for the treatment of cancer
RU2021105387A (ru) Способы и композиции для подавления пути egf/egfr в комбинации с ингибиторами киназы анапластической лимфомы